ACP105 CAS:899821-23-9

ACP-105 est classé comme SARM, et comme tous les autres membres de la famille, il agit en se liant aux récepteurs androgènes dans les tissus musculaires et osseux. Son objectif principal est de fournir des alternatives plus sûres à la plupart des hormones et androgènes anabolisants.. En tant que nouvelle invention, il n’y a aucune littérature derrière l’ACP. Néanmoins, we are still able to dig deeper and find some key information that is helpful to users and potential users. If studied in rats, the compound has a strong anabolic effect similar to testosterone, and has almost no side effects on the prostate of the user.

ACP-105 is a non-steroidal and selective androgen receptor agonist. ACP-105 is part of a class of molecules referred to as selective androgen receptor modulators (SARM). SARMs may advance the standard of treatment for a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer side effects as compared to current treatments based on testosterone replacement. ACP-105 has exhibited promising pharmacological properties and a favorable safety profile in preclinical testing.

In a poster presentation titled, “In Vitro and In Vivo Profile of a Novel Tissue Selective, Orally Bioavailable Non-Steroidal Androgen Receptor Modulator,” ACADIA researchers present findings on ACP-105, a novel non-steroidal SARM.ACP-105 is shown to be as potent and efficacious as testosterone in in vitro assays without interaction at other hormone receptors. en outre, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostrate in preclinical models.